Business
Why the Immutep (ASX:IMM) share price will be in focus today
Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents.
Immutep is a global biotech that is focused on developing immunotherapy therapies for cancer and autoimmune diseases. Its lead product, eftilagimod alpha, is a soluble LAG-3Ig fusion protein based on the LAG-3 which is in clinical development.
New patent added
The Immutep share price could be on the move today following the company’s latest update released after yesterday’s market close
According to its…
-
Noosa News24 hours agoHow a 3D printed aorta helped surgeons replace a ‘ticking time bomb’ inside a man’s chest
-
Noosa News21 hours agoEnsure voices are heard – Proctor
-
Noosa News16 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Noosa News22 hours agoEric Bana Is Back in Murder-Mystery Mode (and in Scenic Surroundings) in the Trailer for New Netflix Series ‘Untamed’